Tech Company M&A Transactions
Scioderm Acquisition
Operating out of Durham, Scioderm was acquired by Amicus Therapeutics. Amicus Therapeutics disclosed that the acquisition price was $847 million.
Transaction Overview
Company Name
Acquired By
Announced On
8/31/2015
Transaction Type
M&A
Amount
$847,000,000
M&A Terms
The $229 million upfront payment for Scioderm consists of $125 million in cash and $104 million in Amicus stock. Amicus will pay Scioderm shareholders another $361 million in cash or stock upon achievement of certain clinical and regulatory milestones and $257 million in cash or stock upon achievement of certain sales milestones.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1007 Slater Road 170
Durham, NC 27703
USA
Durham, NC 27703
USA
Phone
Website
Email Address
Overview
The core business focus of Scioderm is the development of innovative dermatological drugs. Our strategy is to in-license or acquire early to mid-stage pharmaceutical products with the intent to develop the topical products.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Ryan
Chief Scientific Officer
Ron Nardi
VP - Operations
Willistine Lenon
Browse more venture capital transactions:
Prev: 8/31/2015: divvi venture capital transaction
Next: 9/1/2015: Cohero Health venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC transactions on this site come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs